Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL, Young AA, Parkes DG. Nielsen LL, et al. Regul Pept. 2004 Feb 15;117(2):77-88. doi: 10.1016/j.regpep.2003.10.028. Regul Pept. 2004. PMID: 14700743 Review.
Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mari A, et al. Among authors: nielsen ll. Horm Metab Res. 2006 Dec;38(12):838-44. doi: 10.1055/s-2006-956505. Horm Metab Res. 2006. PMID: 17163361 Clinical Trial.
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD. Ratner RE, et al. Among authors: nielsen ll. Diabetes Obes Metab. 2006 Jul;8(4):419-28. doi: 10.1111/j.1463-1326.2006.00589.x. Diabetes Obes Metab. 2006. PMID: 16776749 Clinical Trial.
Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats.
Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA. Gedulin BR, et al. Among authors: nielsen ll. Diabetologia. 2005 Jul;48(7):1380-5. doi: 10.1007/s00125-005-1795-2. Epub 2005 May 25. Diabetologia. 2005. PMID: 15915337
Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS. Taylor K, et al. Among authors: nielsen ll. Horm Metab Res. 2005 Oct;37(10):627-32. doi: 10.1055/s-2005-870529. Horm Metab Res. 2005. PMID: 16278786 Clinical Trial.
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Klonoff DC, et al. Among authors: nielsen ll. Curr Med Res Opin. 2008 Jan;24(1):275-86. doi: 10.1185/030079908x253870. Curr Med Res Opin. 2008. PMID: 18053320 Clinical Trial.
Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes.
Nielsen LL, Okerson T, Holcombe J, Hoogwerf B. Nielsen LL, et al. J Diabetes Sci Technol. 2008 Mar;2(2):255-60. doi: 10.1177/193229680800200214. J Diabetes Sci Technol. 2008. PMID: 19885351 Free PMC article.
Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
Fabunmi R, Nielsen LL, Quimbo R, Schroeder B, Misurski D, Wintle M, Wade R. Fabunmi R, et al. Among authors: nielsen ll. Curr Med Res Opin. 2009 Mar;25(3):777-86. doi: 10.1185/03007990802715199. Curr Med Res Opin. 2009. PMID: 19203299
Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA. Gedulin BR, et al. Among authors: nielsen ll. Int J Pharm. 2008 May 22;356(1-2):231-8. doi: 10.1016/j.ijpharm.2008.01.015. Epub 2008 Jan 17. Int J Pharm. 2008. PMID: 18291606
Investigation of exenatide elimination and its in vivo and in vitro degradation.
Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Copley K, et al. Among authors: nielsen ll. Curr Drug Metab. 2006 May;7(4):367-74. doi: 10.2174/138920006776873490. Curr Drug Metab. 2006. PMID: 16724926
76 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback